Table 4.
Treatment group | Number of entries into bright arena | Time spent in bright arena (s) | Rears in bright arena | Rears in dark arena | Duration of immobility (s) |
---|---|---|---|---|---|
EW control | 1.9 ± 0.2 | 12.4 ± 1.1 | 1.0 ± 0.3 | 14.5 ± 0.9 | 19.8 ± 1.1 |
Alprazolam (0.08 mg/kg) | 3.3 ± 0.4 | 28.6 ± 3.1** | 2.8 ± 0.5 | 17.0 ± 2.1 | 3.5 ± 1.3** |
NR-ANX-C (10 mg/kg) | 2.3 ± 0.4 | 17.0 ± 2.8 | 1.3 ± 0.4 | 13.3 ± 1.5 | 3.2 ± 2.1** |
NR-ANX-C (20 mg/kg) | 2.5 ± 0.3 | 18.8 ± 4.1 | 2.7 ± 0.7 | 17.0 ± 1.9 | 2.8 ± 1.3** |
NR-ANX-C (40 mg/kg) | 3.8 ± 0.6** | 30.7 ± 3.5** | 3.2 ± 0.5* | 19.5 ± 2.5 | 2.7 ± 1.3** |
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett's Multiple Comparison test. *P < .05; **P < .01.